{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":23,"n_cols":5,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910972915603321"]
[null,null,"Autore",null,"Lacroix Marc <1963->"]
[null,null,"Titolo",null,"Molecular therapy of breast cancer : classicism meets modernity / / Marc Lacroix"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Nova Biomedical Books, c2009"]
[null,null,"ISBN",null,"1-60876-726-4"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (303 p.)"]
[null,null,"Collana",null,"Cancer etiology, diagnosis and treatments series"]
[null,null,"Disciplina",null,"362.196/99449"]
[null,null,"Soggetti",null,"Breast - Cancer - Molecular aspects"]
[{"$nulls":4},"Antineoplastic agents"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"\"\"Molecular Therapy of Breast Cancer: Classicism Meets Modernity\"\"; \"\"Dedication\"\"; \"\"Contents \"\"; \"\"Preface\"\"; \"\"Introduction \"\"; \"\"References \"\"; \"\"Selective Estrogen Receptor Modulators (SERMs) and Down-Regulators (SERDs)\"\"; \"\"Abstract \"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Selective Estrogen Receptor Modifiers (SERMs) \"\"; \"\"Tamoxifen \"\"; \"\"Toremifene \"\"; \"\"Fulvestrant \"\"; \"\"Conclusion \"\"; \"\"References \"\"; \"\"Aromatase Inhibitors \"\"; \"\"Abstract \"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Anastrozole \"\"; \"\"Letrozole \"\"; \"\"Exemestane \"\""]
[{"$nulls":4},"\"\"Conclusion \"\"\"\"References \"\"; \"\"Agents Inducing Ovarian Suppression \"\"; \"\"Abstract \"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Goserelin \"\"; \"\"Triptorelin\"\"; \"\"Leuprolide \"\"; \"\"Conclusion \"\"; \"\"References \"\"; \"\"Antimetabolites \"\"; \"\"Abstract \"\"; \"\"Introduction\"\"; \"\"Clinical Trials in January 2009  \"\"; \"\"Fluorouracil \"\"; \"\"Capecitabine \"\"; \"\"Gemcitabine \"\"; \"\"Pemetrexed \"\"; \"\"Methotrexate \"\"; \"\"Conclusion \"\"; \"\"References\"\"; \"\"Alkylating Agents \"\"; \"\"Abstract \"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Cyclophosphamide \"\""]
[{"$nulls":4},"\"\"Platinum Compounds (Cisplatin, Carboplatin, Oxaliplatin, Picoplatin) - Generalities \"\"\"\"Cisplatin \"\"; \"\"Carboplatin \"\"; \"\"Oxaliplatin \"\"; \"\"Picoplatin \"\"; \"\"Temozolomide \"\"; \"\"Thiotepa\"\"; \"\"Ifosfamide \"\"; \"\"Melphalan \"\"; \"\"Busulfan \"\"; \"\"Conclusion \"\"; \"\"References \"\"; \"\"Anthracyclines \"\"; \"\"Abstract \"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Doxorubicin \"\"; \"\"Liposomal Doxorubicin \"\"; \"\"Epirubicin \"\"; \"\"Conclusion \"\"; \"\"References\"\"; \"\"Microtubule-Binding Agents \"\"; \"\"Abstract \"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Taxanes - Generalities \"\""]
[{"$nulls":4},"\"\"Larotaxel \"\"\"\"Docetaxel \"\"; \"\"Paclitaxel and Nab-Paclitaxel \"\"; \"\"Epothilones - Generalities \"\"; \"\"Ixabepilone \"\"; \"\"Patupilone \"\"; \"\"Sagopilone \"\"; \"\"Vinca Alkaloids - Generalities \"\"; \"\"Vinorelbine\"\"; \"\"Vinflunine \"\"; \"\"Eribulin \"\"; \"\"Conclusion \"\"; \"\"References \"\"; \"\"Topoisomerase Inhibitors \"\"; \"\"Abstract \"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Irinotecan \"\"; \"\"Etoposide \"\"; \"\"Conclusion \"\"; \"\"References\"\"; \"\"HER Family Inhibitors \"\"; \"\"Abstract\"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Trastuzumab \"\"; \"\"Lapatinib \"\"; \"\"Gefitinib \"\""]
[{"$nulls":4},"\"\"Erlotinib \"\"\"\"Pertuzumab \"\"; \"\"Cetuximab \"\"; \"\"Ertumaxomab \"\"; \"\"Neratinib \"\"; \"\"Trastuzumab-MCC-DM1 \"\"; \"\"BIBW 2992 \"\"; \"\"ARRY-334543 \"\"; \"\"Conclusion \"\"; \"\"References \"\"; \"\"Angiogenesis Inhibitors \"\"; \"\"Abstract\"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009 \"\"; \"\"Bevacizumab\"\"; \"\"Sunitinib \"\"; \"\"Vandetanib \"\"; \"\"Pazopanib \"\"; \"\"Ramucirumab \"\"; \"\"ABT-869 \"\"; \"\"AV-951 \"\"; \"\"PTC299\"\"; \"\"AMG 386 \"\"; \"\"Aflibercept \"\"; \"\"Conclusion\"\"; \"\"References \"\"; \"\"Insulin-Like Growth Factor-I Receptor (IGF-1R) Inhibitors\"\"; \"\"Abstract\"\"; \"\"Introduction \"\"; \"\"Clinical Trials in January 2009\"\""]
[{"$nulls":4},"\"\"Cixutumumab\"\""]
[null,null,null,"Sommario/riassunto","Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. This book offers an insight into current developments of breast cancer therapy, when classicism meets modernity."]